Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. COLL
COLL logo

COLL Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Collegium Pharmaceutical Inc (COLL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
36.440
1 Day change
-2.75%
52 Week Range
50.790
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

COLL is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is holding near resistance with mixed technicals, weak sentiment from insider selling, and no recent news catalyst or strong proprietary buy signal. I would not buy it immediately; I would wait for a cleaner setup or stronger fundamental/analyst confirmation.

Technical Analysis

Price closed at 37.035, slightly above the prior close of 37.03, with a recent +3.23% move. MACD histogram is positive and expanding, which supports short-term upside momentum. However, RSI_6 is around 70.3, suggesting the stock is getting stretched, and moving averages are converging rather than showing a decisive breakout trend. Key levels matter here: pivot 35.23, resistance 36.957 and R2 38.023. Since price is already near the first resistance zone and only modestly above it, the setup is not an attractive immediate entry for a beginner long-term buyer.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bearish-to-neutral on positioning because put open interest (661) is significantly above call open interest (313), producing a put-call open interest ratio of 2.11. That often reflects downside hedging or bearish expectations. The volume picture is extremely thin today with only 3 total option contracts traded, so the latest day’s flow is not very informative. Implied volatility is elevated at 71.02 with IV percentile 93.25, which means options are expensive relative to history. Overall, options data does not support an aggressive buy here.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
6

Positive Catalysts

  • No news in the recent week, so there is no fresh event-driven catalyst. The only positive factors are a bullish MACD reading and the stock’s recent short-term price improvement. Similar candlestick analysis suggests only modest near-term upside probability.

Neutral/Negative Catalysts

  • Insiders are selling, and selling has increased 145.95% over the last month, which is a clear negative sentiment signal. Hedge funds are neutral with no meaningful accumulation trend. There is no recent news flow, no congress trading activity, and no strong proprietary buy signal from AI Stock Picker or SwingMax. Options positioning is also skewed bearish with a 2.11 put-call open interest ratio.

Financial Performance

No usable financial snapshot was provided for the latest quarter, so I cannot confirm revenue or earnings growth trends. Because the latest quarter season is unavailable, there is no fundamental evidence here strong enough to justify a long-term beginner buy.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible Wall Street upgrade cycle or target revision support. Based on the available data, Wall Street evidence appears limited and not convincingly bullish. Pros: some short-term technical momentum. Cons: insider selling, bearish options positioning, no recent catalyst, and no strong buy signal.

Wall Street analysts forecast COLL stock price to rise
4 Analyst Rating
Wall Street analysts forecast COLL stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 37.470
sliders
Low
55
Averages
56.75
High
60
Current: 37.470
sliders
Low
55
Averages
56.75
High
60
Truist
Les Sulewski
Buy
maintain
$55 -> $58
AI Analysis
2026-02-10
Reason
Truist
Les Sulewski
Price Target
$55 -> $58
AI Analysis
2026-02-10
maintain
Buy
Reason
Truist analyst Les Sulewski raised the firm's price target on Collegium Pharmaceutical to $58 from $55 and keeps a Buy rating on the shares. The firm is positive on the company's Jornay momentum and pain portfolio durability, the analyst tells investors in a research note.
Barclays
Overweight
downgrade
$58 -> $56
2026-01-09
Reason
Barclays
Price Target
$58 -> $56
2026-01-09
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Collegium Pharmaceutical to $56 from $58 and keeps an Overweight rating on the shares. The firm updated the company's' estimates to reflect its initial fiscal 2026 outlook.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for COLL
Unlock Now

People Also Watch